<DOC>
	<DOCNO>NCT01536041</DOCNO>
	<brief_summary>The primary objective study : i. determine effect single oral dos ( 20 200 mg ) ONO-6950 versus placebo exercise induce bronchoconstriction ( EIB ) percent attenuation decrease force expiratory volume 1 second ( FEV1 ) exercise challenge ii . determine safety tolerability single dose administration 20 200 mg ONO-6950 asthmatic patient . The secondary objective study : i. compare effect different ( 20 200 mg ) single oral dos ONO-6950 versus montelukast ( 10 mg ) EIB percent attenuation decrease FEV1 exercise challenge ii . determine ratio responders/non-responders FEV1 different ( 20 200 mg ) single oral dos ONO-6950 comparison montelukast ( 10 mg ) placebo .</brief_summary>
	<brief_title>A Placebo Active Controlled Study ONO-6950 Asthmatic Patients</brief_title>
	<detailed_description>The study examine ONO-6950 could alleviate EIB asthmatic patient . Eligible patient complete randomize , double-blind , four-way crossover study . During four evaluation period , patient administer single dose either 20 200 mg ONO-6950 , 10 mg Montelukast , placebo . Each evaluation period include various assessment follow exercise challenge ambulatory setting .</detailed_description>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Patients gender , 18 60 year age , bronchial asthma least 6 month history exercise induce bronchospasm Patients FEV1 ≥ 70 % predict withhold shortacting β agonist least 8 hour prior test Screening exercise challenge demonstrate patient experience fall FEV1 ≥ 20 % Nonsmokers free usage nicotinecontaining product least year prior screen Previous history lifethreatening asthma , respiratory tract infection and/or exacerbation asthma within 6 week prior first screen visit History unable tolerate complete exercise challenge clinically significant multiple drug food allergy Past present disorder diseases include , limited cardiovascular , malignancy , hepatic , renal , hematological , neurological , psychiatric , endocrine , pulmonary asthma Patients Seasonal Allergic Rhinitis ( SAR ) seasonal allergic asthma , significant symptom may confound study assessment Significant safety laboratory , ECG , vital sign abnormality would place patient undue risk study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>asthma</keyword>
	<keyword>Adult</keyword>
</DOC>